Abbott Issues Updated 2021 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Abbott Laboratories (ABT) Falls After Cutting Full-Year Outlook on Lower Demand for Covid-19 Tests
June 1, 2021 10:56 AM EDTShares of Abbott Laboratories (NYSE: ABT) are down 6.5% in todays trading session after the company issued an updated 2021 outlook to reflect lower demand from its diagnostic unit.
The company cited significantly lower recent and projected COVID-19 diagnostic testing demand amid an accelerated vaccination activity.
Hence, the company now expects full-year 2021 EPS of $2.75 to $2.95 and full-year adjusted EPS of $4.30 to $4.50, below the consensus of... More
